Introduction {#s1}
============

The [Reproducibility Project: Cancer Biology](https://osf.io/e81xl/wiki/home/) (RP:CB) is a collaboration between the [Center for Open Science](https://cos.io) and [Science Exchange](https://www.scienceexchange.com) that seeks to address concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology ([@bib8]). For each of these papers a Registered Report detailing the proposed experimental designs and protocols for the replications was peer reviewed and published prior to data collection. The present paper is a Replication Study that reports the results of the replication experiments detailed in the Registered Report ([@bib19]) for a paper by Poliseno et al., and uses a number of approaches to compare the outcomes of the original experiments and the replications.

In 2010, Poliseno et al. reported *PTENP1*, the pseudogene of the tumor suppressor PTEN, acted as a repressor (molecular sponge) of PTEN-targeting microRNAs and, in turn, regulated cellular PTEN expression and function. Pseudogenes are non-coding genomic DNA sequences that share high sequence similarity with their cognate protein-coding genes ([@bib13]). The 3'UTR sequences of *PTEN* and *PTENP1* share common putative microRNA binding site and overexpression of *miR-19b* and *miR-20a* in the prostate cancer cell line DU145 resulted in decreased *PTEN* and *PTENP1* mRNA levels ([@bib28]). The regulatory role of *PTENP1* was demonstrated in knockdown experiments where reduction of *PTENP1* resulted in decreased *PTEN* mRNA and PTEN protein levels and increased proliferation of DU145 cells ([@bib28]). Similar biological activity of the 3'UTR of *PTEN* was also reported where overexpression of *PTEN* 3'UTR derepressed *PTENP1* expression and inhibited DU145 proliferation ([@bib28]).

The Registered Report for the paper by Poliseno et al. described the experiments to be replicated (Figures 1D, 2F--H and 4A), and summarized the current evidence for these findings ([@bib19]). Since that publication additional studies have reported the biological activity of *PTENP1* in various tumors. In esophageal squamous cell carcinoma ([@bib12]) and oral squamous cell carcinoma ([@bib10]), overexpression of *PTENP1* decreased proliferation and colony formation *in vitro* and inhibited tumor growth in xenograft models. In head and neck squamous cell carcinoma ([@bib24]), hepatocellular carcinoma ([@bib5]; [@bib29]), and bladder cancer ([@bib43]), *PTENP1* overexpression increased *PTEN* mRNA expression and decreased proliferation, colony formation, invasion, and migration *in vitro* and inhibited growth in xenograft models. In gastric cancer, *PTENP1* overexpression led to increased *PTEN* mRNA and PTEN protein levels, decreased cell proliferation and induced apoptosis, and inhibited migration and invasive ability of gastric cancer cells ([@bib42]). In clear-cell renal cell carcinoma overexpression of *PTENP1* in cells reduced cell proliferation, migration, and invasion *in vitro* and tumor growth and metastasis in xenograft models ([@bib41]). Overexpression of *PTENP1* was reported to decrease proliferation, colony formation, and migration in the breast cancer cell line MCF7 ([@bib6]; [@bib11]; [@bib33]), while [@bib40] reported decreased *PTEN* mRNA expression and accelerated MCF7 tumor growth. However, in ER-negative breast cancer cells, *PTENP1* upregulation increased *PTEN* mRNA expression and inhibited tumor progression ([@bib11]; [@bib22]; [@bib33]; [@bib40]). Additional competing endogenous RNAs (ceRNAs) that modulate *PTEN* through microRNA competition were identified using a computational model expanding upon the work reported in [@bib28] to propose a unifying hypothesis of regulatory networks composed of ceRNAs ([@bib34]). In addition to *PTEN*/*PTENP1*, the pseudogene of oncogenic *BRAF*, *BRAFP1* has been reported to regulate BRAF expression and subsequently affect MAPK signaling and proliferation, and drive tumorigenesis *in vivo* ([@bib18]). Recently, it has also been reported an extensive gene/pseudogene network that is comprised of multiple microRNAs and multiple pseudogenes derived from a single parental gene ([@bib4]) with the potential of thousands of novel pseudogene-gene associations beginning to be explored through bioinformatic tools that have been developed ([@bib17]).

The outcome measures reported in this Replication Study will be aggregated with those from the other Replication Studies to create a dataset that will be examined to provide evidence about reproducibility of cancer biology research, and to identify factors that influence reproducibility more generally.

Results and discussion {#s2}
======================

Cell growth assay following siRNA transfection {#s2-1}
----------------------------------------------

We independently replicated an experiment to examine the consequences of *PTEN* and/or *PTENP1* downregulation on DU145 cell proliferation. This experiment was described in Protocol 2 in the Registered Report ([@bib19]) and is similar to Figure 2H of [@bib28] that reported *PTENP1* downregulation accelerated cell proliferation with the strongest effect observed when *PTEN* and *PTENP1* were both silenced. We utilized the same designed custom siRNA pools as the original study to specifically target either *PTEN* or *PTENP1*, as well as a commercially available *PTEN* siRNA pool that binds common sequences in *PTEN* and *PTENP1*. Proliferative activity was determined using the crystal violet assay each day after transfection for a total of 5 days with results presented relative to the values at the start of the time course for each condition (i.e., for each condition the average relative cell number at the start of the time course was set to 1) ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). We found that compared to cells transfected with non-targeting siRNA (average Day 5 relative cell number (Avg Day 5\#) = 10.2), there was increased cell proliferation when cells were transfected with either the *PTENP1* specific siRNA (Avg Day 5\# = 24.1) or the siRNA pool targeting *PTEN* and *PTENP1* (Avg Day 5\# = 25.0). Additionally, there was a minor increase in cell proliferation when cells were transfected with the *PTEN* specific siRNA (Avg Day 5\# = 12.2). Interestingly, untransfected cells, a condition not reported in the original study, displayed a cell proliferation profile (Avg Day 5\# = 21.3) more similar to cells transfected with either the *PTENP1* specific siRNA or the siRNA pool targeting *PTEN* and *PTENP1* than the non-targeting siRNA. This could be a result of transfection-mediated cytotoxicity and/or off-target siRNA effects that can generate cellular stress leading to decreased cell growth ([@bib1]; [@bib9]; [@bib39]) and is a factor to consider when interpreting these results, especially when considering the low level of increased cell growth in cells depleted of *PTEN* despite efficient knockdown ([Figure 2A](#fig2){ref-type="fig"}). The original study reported increased cell proliferation, compared to non-targeting siRNA, when cells were transfected with either the *PTEN* specific siRNA (Avg Day 5\# = 4.15) or the *PTENP1* specific siRNA (Avg Day 5\# = 2.61), with the strongest effect being observed when cells were transfected with the siRNA pool targeting *PTEN* and *PTENP1* (Avg Day 5\# = 5.41) ([@bib28]). In the original study the control condition (cells transfected with non-targeting siRNA) had a minimal impact on cell proliferation during the course of the experiment (Avg Day 5\# = 1.60) ([@bib28]). Importantly, the results of both studies should take into consideration that the doubling time for DU145 cells has been reported as \~29 hr ([@bib23]), which would correspond to an Avg Day 5\# of \~18, assuming cells maintained exponential phase growth. Additionally, the difference in achieved knockdown between the original study and this replication attempt is a possible reason for the differences in outcomes between the two studies. The experiment that assessed the level of knockdown in this replication is described in the section below ([Figure 2](#fig2){ref-type="fig"}) and compared to the results reported in the original study. Various levels of downregulation can give various phenotype effects, thus a higher level of knockdown might be required to observe an effect with this experimental design. Although, observing different outcomes are informative to establish the range of conditions under which a given phenotype can be observed ([@bib2]).

![Cell growth of DU145 cells depleted of *PTEN* and/or *PTENP1*.\
DU145 cells were transfected with either a non-targeting siRNA (siLUC), si-PTEN, si-PTENP1, or an siRNA pool targeting *PTEN* and *PTENP1* (si-PTEN/PTENP1), or not transfected. Crystal violet proliferation assays were performed each day as indicated starting the day after transfection. Relative cell number was calculated relative to the average Day 0 values for each condition. Means reported and error bars represent *SD* from five independent biological repeats. Two-way ANOVA interaction between *PTEN* (targeted or not-targeted) and *PTENP1* (targeted or not-targeted) on Day 5 relative cell numbers: *F*(1,16) = 0.02, *p*=0.878; main effect of *PTEN: F*(1,16) = 0.15, *p*=0.703; main effect of *PTENP1: F*(1,16) = 13.8, *p*=0.0019. Planned contrasts between siLUC and si-PTEN: *t*(16) = 0.38, uncorrected *p*=0.705 with *a priori* Bonferroni adjusted significance threshold of 0.01, Bonferroni corrected *p*\>0.99; siLUC and si-PTENP1: *t*(16) = 2.73, uncorrected *p*=0.015, Bonferroni corrected *p*=0.074; siLUC and si-PTEN/PTENP1: *t*(16) = 2.90, uncorrected *p*=0.011, Bonferroni corrected *p*=0.053; si-PTEN/PTENP1 and si-PTEN: *t*(16) = 2.51, uncorrected *p*=0.023, Bonferroni corrected *p*=0.115; si-PTEN/PTENP1 and si-PTENP1: *t*(16) = 0.16, uncorrected *p*=0.872, Bonferroni corrected *p*\>0.99. Additional details for this experiment can be found at <https://osf.io/kjmxj/>.](elife-51019-fig1){#fig1}

![*PTEN* and *PTENP1* abundance in DU145 cells depleted of *PTEN* and/or *PTENP1*.\
DU145 cells were transfected with either a non-targeting siRNA (siLUC), si-PTEN, si-PTENP1, or an siRNA pool targeting *PTEN* and *PTENP1* (si-PTEN/PTENP1), or not transfected. Total RNA was isolated 24 hr later and qRT-PCR analysis was performed to detect *PTEN*, *PTENP1*, and *ß-ACTIN* levels. (**A**) Fold change in *PTEN* expression (*PTEN*/*ß-ACTIN*) is presented for each condition relative to siLUC cells. Means reported and error bars represent *SD* from five independent biological repeats. Two-way ANOVA interaction between *PTEN* (targeted or not-targeted) and *PTENP1* (targeted or not-targeted) on *PTEN* expression: *F*(1,16) = 0.41, *p*=0.532; main effect of *PTEN: F*(1,16) = 35.5, *p*=2.01×10^−5^; main effect of *PTENP1: F*(1,16) = 0.21, *p*=0.651. Planned contrasts between siLUC and si-PTEN for *PTEN* expression: *t*(16) = 4.66, uncorrected *p*=0.00026 with *a priori* Bonferroni adjusted significance threshold of 0.0083, Bonferroni corrected *p*=0.0016; siLUC and si-PTENP1: *t*(16) = 0.78, uncorrected *p*=0.448, Bonferroni corrected *p*\>0.99; siLUC and si-PTEN/PTENP1: *t*(16) = 4.54, uncorrected *p*=0.00034, Bonferroni corrected *p*=0.0020. (**B**) Fold change in *PTENP1* expression (*PTENP1*/*ß-ACTIN*) is presented for each condition relative to siLUC cells. Means reported and error bars represent *SD* from five independent biological repeats. Two-way ANOVA interaction on *PTENP1* expression: *F*(1,16) = 2.03, *p*=0.174; main effect of *PTEN*: F(1,16) = 0.019, *p*=0.891; main effect of *PTENP1: F*(1,16) = 16.6, *p*=0.00088. Planned contrasts between siLUC and si-PTEN for *PTENP1* expression: *t*(16) = 1.10, uncorrected *p*=0.286 with *a priori* Bonferroni adjusted significance threshold of 0.0083, Bonferroni corrected *p*\>0.99; siLUC and si-PTENP1: *t*(16) = 3.89, uncorrected *p*=0.0013, Bonferroni corrected *p*=0.0079; siLUC and si-PTEN/PTENP1: *t*(16) = 2.98, uncorrected *p*=0.0089, Bonferroni corrected *p*=0.053. Additional details for this experiment can be found at <https://osf.io/4uard/>.](elife-51019-fig2){#fig2}

The analysis plan specified in the Registered Report ([@bib19]) proposed to compare the Avg Day 5\# for the cells transfected with the various siRNAs. To test if downregulation of *PTEN* and/or *PTENP1*, was effective in increasing DU145 cell proliferation we performed an analysis of variance (ANOVA). The ANOVA result was statistically significant for the *PTENP1* main effect (*F*(1,16) = 13.8, *p*=0.0019). Thus, the null hypothesis that there is no difference in cell proliferation when *PTENP1* is downregulated, whether there was or was not downregulation of *PTEN*, can be rejected. The main effect for *PTEN* downregulation (*F*(1,16) = 0.15, *p*=0.703) and the interaction (*F*(1,16) = 0.02, *p*=0.878) were not statistically significant. We planned to conduct five comparisons using the Bonferroni correction to adjust for multiple comparisons, making the *a priori* adjusted significance threshold 0.01. According to this criterion, none of the planned comparisons were statistically significant (see [Figure 1](#fig1){ref-type="fig"} figure legend). The same analysis was conducted using area under the curve (AUC) during the timecourse for each biological repeat, which gave similar results ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). To summarize, for this experiment we found results that were generally in the same direction as the original study (i.e., increased cell proliferation when *PTEN* and/or *PTENP1* were downregulated compared to non-targeting siRNA) and not statistically significant where predicted.

Quantitative PCR following transfection with siRNA against PTEN and/or PTENP1 {#s2-2}
-----------------------------------------------------------------------------

To determine the knockdown efficiency of *PTEN* and *PTENP1* in DU145 cells we performed qRT-PCR following transfection with the same siRNAs targeting *PTEN* and/or *PTENP1* described above. This experiment also tested whether *PTENP1* knockdown resulted in decreased *PTEN* mRNA, and vice versa. This is similar to what was reported in Figure 2G of [@bib28] and described in Protocol 3 in the Registered Report ([@bib19]). We found that compared to cells transfected with non-targeting siRNA (mean relative expression = 1.00), cells transfected with *PTEN* specific siRNA or the siRNA pool targeting *PTEN* and *PTENP1* resulted in decreased *PTEN* expression with relative mean values of 0.298 and 0.317, respectively, which were both statistically significant (non-targeting vs. si-PTEN: *t*(16) = 4.66, uncorrected *p*=0.00026, corrected *p*=0.0016; non-targeting vs. si-PTEN/PTENP1: *t*(16) = 4.54, uncorrected *p*=0.00034, corrected *p*=0.0020) ([Figure 2A](#fig2){ref-type="fig"}). Cells transfected with *PTENP1* specific siRNA, however, resulted in a slight decrease in *PTEN* expression (mean relative expression = 0.883), which was not statistically significant (*t*(16) = 0.78, uncorrected *p*=0.448, corrected *p*\>0.99). Similarly, cells transfected with *PTENP1* specific siRNA or the siRNA pool targeting *PTEN* and *PTENP1*, resulted in decreased relative *PTENP1* expression with relative mean values of 0.287 and 0.453, respectively; while *PTENP1* expression was slightly decreased following transfection with *PTEN* specific siRNA (mean relative expression = 0.797) ([Figure 2B](#fig2){ref-type="fig"}). According to the criterion predefined in the Registered Report, cells transfected with *PTENP1* specific siRNA were statistically significant (non-targeting vs. si-PTENP1: *t*(16) = 3.89, uncorrected *p*=0.0013, corrected *p*=0.0079), while the other two comparisons were not (non-targeting vs. si-PTEN/PTENP1: *t*(16) = 2.98, uncorrected *p*=0.0089, corrected *p*=0.053; non-targeting vs. si-PTEN: *t*(16) = 1.10, uncorrected *p*=0.286, corrected *p*\>0.99). The original study reported statistically significant decreases in *PTEN* and *PTENP1* expression for all of the comparisons between cells transfected with non-targeting siRNA and either si-PTEN, si-PTENP1, or the siRNA pool targeting *PTEN* and *PTENP1*. In the original study *PTEN* expression was decreased with relative mean values of \~0.12, \~0.38, and \~0.19 and *PTENP1* expression was decreased with relative mean values of \~0.54, \~0.27, and \~0.48 for si-PTEN, si-PTENP1, and si-PTEN/PTENP1, respectively ([@bib28]). Further, these replication and original results used *ß-ACTIN* as the internal standard to normalize *PTEN* and *PTENP1* expression. We also normalized the *PTEN* and *PTENP1* levels from this experiment to *36B4*, as suggested during peer review of the Registered Report ([@bib7]), and found similar results ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). To summarize, for this experiment we found results that were in the same direction as the original study and statistically significant for confirming knockdown of *PTEN* or *PTENP1* with target specific siRNA; however results were not statistically significant for other comparisons (i.e., *PTEN* mRNA levels following *PTENP1* knockdown, and vice versa).

There are a number of factors that could affect these experiments and should be considered when interpreting these data. Although qRT-PCR is a common laboratory technique there are a number of steps and reagents that can vary in experimental protocols and data analyses among different laboratories ([@bib21]; [@bib26]; [@bib35]). While this replication attempted to mirror the approach taken in the original study it was limited to what was obtainable from the original paper and through communication with the original authors. Similarly, the raw data (e.g., levels of *ß-ACTIN* in the PCR reaction) from the original study were unknown and thus can not be directly compared to this replication attempt. Additionally, cell to cell contact has been reported to active microRNA biogenesis globally ([@bib16]). Thus, the level of cellular confluence, which was not able to be compared between the original study and this replication attempt, is another factor that needs to be considered. Finally, the higher variability observed in this study is one of the factors that could influence if statistical significance is reached, particularly since the sample size of this replication attempt was determined *a priori* to detect the effect based on the originally reported data.

Western blot of cells transfected with siRNA {#s2-3}
--------------------------------------------

We also examined the knockdown efficiency and impact of *PTENP1* knockdown on PTEN protein levels using the same siRNAs targeting *PTEN* and/or *PTENP1* described above and the same PTEN antibody as the original study. This is similar to what was reported in Figure 2H of [@bib28] and described in Protocol 4 in the Registered Report ([@bib19]). We found that compared to cells transfected with non-targeting siRNA (mean relative expression = 1.00), cells transfected with *PTEN* specific siRNA, *PTENP1* specific siRNA, or the siRNA pool targeting *PTEN* and *PTENP1* resulted in decreased PTEN expression with relative mean values of 0.41, 0.65, and 0.17, respectively ([Figure 3](#fig3){ref-type="fig"}). The original study reported that compared to non-targeting siRNA (relative expression = 1.00) the relative PTEN expression was 0.50 for cells transfected with *PTEN* specific siRNA, 0.60 for cells transfected with *PTENP1* specific siRNA, and 0.10 for cells transfected with the siRNA pool targeting *PTEN* and *PTENP1*.

![PTEN expression in DU145 cells depleted of *PTEN* and/or *PTENP1*.\
DU145 cells were transfected with either a non-targeting siRNA (siLUC), si-PTEN, si-PTENP1, or an siRNA pool targeting *PTEN* and *PTENP1* (si-PTEN/PTENP1), or not transfected. Cells were harvested 48 hr later for Western blot analysis. (**A**) Relative protein expression (PTEN/HSP90) are presented for each condition. Western blot bands were quantified, PTEN levels were normalized to HSP90, then for each biological repeat values were normalized to the untransfected condition with protein expression presented relative to siLuc. Dot plot of independent biological repeats (n = 5), means reported as crossbars and error bars represent 95% CI. Data reported in Figure 2H of [@bib28] is displayed as a single point (small dark red circle) for comparison. Planned comparisons (two-tailed Wilcoxon-Mann-Whitney tests): siLUC and si-PTEN: *U* = 25, uncorrected *p*=0.0079 with *a priori* Bonferroni adjusted significance threshold of 0.01, Bonferroni corrected *p*=0.040; siLUC and si-PTENP1: *U* = 21, uncorrected *p*=0.095, Bonferroni corrected *p*=0.476; siLUC and si-PTEN/PTENP1: *U* = 25, uncorrected *p*=0.0079, Bonferroni corrected *p*=0.040; si-PTEN/PTENP1 and si-PTEN: *U* = 6, uncorrected *p*=0.222, Bonferroni corrected *p*\>0.99; si-PTEN/PTENP1 and si-PTENP1: *U* = 0, uncorrected *p*=0.0079, Bonferroni corrected *p*=0.040. (**B**) Representative Western blots probed with an anti-PTEN antibody (two exposures presented to facilitate detection) and anti-HSP90 antibody. Relative PTEN/HSP90 expressions are reported below PTEN images. Additional details for this experiment can be found at <https://osf.io/re87y/>.](elife-51019-fig3){#fig3}

To compare the relative PTEN expression among the various conditions, we planned to conduct five comparisons using the Bonferroni correction to adjust for multiple comparisons, making the *a priori* adjusted significance threshold 0.01. Using the Wilcoxon-Mann-Whitney test we found statistically significant differences between non-targeting siRNA and si-PTEN (*U* = 25, uncorrected *p*=0.0079, corrected *p*=0.040), non-targeting siRNA and si-PTEN/PTENP1 (*U* = 25, uncorrected *p*=0.0079, corrected *p*=0.040), and si-PTENP1 and si-PTEN/PTENP1 (*U* = 0, uncorrected *p*=0.0079, corrected *p*=0.040). The comparisons between non-targeting siRNA and si-PTENP1 (*U* = 21, uncorrected *p*=0.095, corrected *p*=0.476) and si-PTEN and si-PTEN/PTENP1 (*U* = 6, uncorrected *p*=0.222, corrected *p*\>0.99) were not statistically significant. To summarize, for this experiment we found results that were in the same direction as the original study with statistically significant decreases in relative PTEN expression from cells transfected with si-PTEN or si-PTEN/PTENP1 compared to non-targeting siRNA or si-PTENP1, while the differences in relative PTEN expression between non-targeting siRNA and si-PTENP1, and si-PTEN and si-PTEN/PTENP1, were not statistically significant.

Quantitative PCR following *PTEN* 3′ UTR transfection {#s2-4}
-----------------------------------------------------

DU145 cells were transfected with a plasmid designed to express the *PTEN* 3'UTR to test if the *PTEN* 3'UTR exerted a biological role on *PTENP1*. This was described in Protocol 5 in the Registered Report ([@bib19]) and is similar to Figure 4A of [@bib28] that reported *PTEN* 3'UTR derepressed *PTENP1* abundance. We found *PTENP1* abundance was similar and not statistically significant (two sample *t* test: *t*(4) = 0.46, *p*=0.671) between cells transfected with a vector control plasmid (mean relative expression = 1.00) and cells transfected with *PTEN* 3'UTR (mean relative expression = 0.95) ([Figure 4](#fig4){ref-type="fig"}). The original study reported a statistically significant increase in *PTENP1* expression when cells were transfected with a plasmid that expressed the *PTEN* 3'UTR (mean relative expression = \~3.88) compared to vector control (mean relative expression = 1.00) ([@bib28]). Similar to the above experiments, these results used *ß-ACTIN* as the internal standard to normalize *PTENP1* expression; however when we used *36B4* to normalize *PTENP1* levels we found similar results ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). To summarize, for this experiment we found results that were not in the same direction as the original study and not statistically significant where predicted. The level of *PTEN* 3'UTR expression was not determined for this experiment and thus is a possible reason for differences in outcomes between the original study and this replication attempt. Additionally, as noted above, potential differences between the original study and this replication attempt are factors that need to be considered when interpreting these results. These include, but are not limited to, variations in expression levels of the internal standards used to normalize *PTENP1* expression, differences in observed biological variability between the original study and this replication attempt, and cellular confluence, which has been reported to modify the levels of microRNA expression and thus their target constructs ([@bib16]).

![*PTENP1* abundance in DU145 cells expressing *PTEN* 3'UTR.\
DU145 cells were transfected with either a vector control plasmid (pCMV) or a plasmid to express *PTEN* 3'UTR (pCMV-*PTEN*), or not transfected. Total RNA was isolated 24 hr later and qRT-PCR analysis was performed to detect *PTENP1* and *ß-ACTIN* levels. Fold change in *PTENP1* expression (*PTENP1*/*ß-ACTIN*) is presented for each condition relative to pCMV transfected cells. Means reported and error bars represent *SD* from three independent biological repeats. Unpaired two-tailed Student's *t* test between pCMV and pCMV-*PTEN: t*(4) = 0.46, *p*=0.671. Additional details for this experiment can be found at <https://osf.io/rkuxh/>.](elife-51019-fig4){#fig4}

Cell growth assay following *PTEN* 3′ UTR transfection {#s2-5}
------------------------------------------------------

The impact of *PTEN* 3'UTR overexpression on DU145 cell proliferation was also examined. This is similar to what was reported in Figure 4A of [@bib28] and described in Protocol 6 in the Registered Report ([@bib19]). Using the crystal violet assay, proliferative activity was determined each day after transfection for a total of 5 days with results presented relative to the values at the start of the timecourse for each condition (same approach as described above) ([Figure 5](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). We found that compared to cells transfected with a vector control plasmid (Avg Day 5\# = 3.79), there was growth inhibition observed when cells were transfected with *PTEN* 3'UTR (Avg Day 5\# = 2.72), which was statistically significant (two sample *t* test: *t*(4) = 9.25, *p*=0.00076). The same analysis was conducted using AUC during the 5 day timecourse for each biological repeat, which gave similar results ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). In addition, untransfected cells displayed a cell proliferation profile similar to the vector control ([Figure 5](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). In the original study, overexpression of *PTEN* 3'UTR inhibited cell proliferation (Avg Day 5\# = \~5.24) compared to vector control (Avg Day 5\# = \~7.17) ([@bib28]). Interestingly, the growth profiles of the control conditions differed between this experiment and the experiment described above where DU145 cells were transfected with different siRNAs. Importantly, in this replication attempt this experiment and the cell growth assay presented in [Figure 1](#fig1){ref-type="fig"} were conducted by two independent labs, therefore operator and/or environmental differences could be contributing factors. This could also be the result of cells being in the lag phase of cell growth at the start of the experiment instead of exponential phase growth, which could be caused by the seeding density and/or the *in vitro* age of the cultures ([@bib32]). The original study also reported different cell growth profiles between the control conditions in the knockdown and overexpression experiments. Furthermore, the growth inhibition observed in the original study in cells that overexpressed *PTEN* 3'UTR was correlated with an increase in *PTENP1* abundance, which, as described above ([Figure 4](#fig4){ref-type="fig"}), was not observed in this replication attempt. To summarize, for this experiment we found results that were in the same direction as the original study and statistically significant where predicted.

![Cell growth of DU145 cells expressing *PTEN* 3'UTR.\
DU145 cells were transfected with either vector control plasmid (pCMV) or a plasmid to express PTEN 3'UTR (pCMV-*PTEN*), or not transfected. Crystal violet proliferation assays were performed each day as indicated starting the day after transfection. Relative cell number was calculated relative to the average Day 0 values for each condition. Means reported and error bars represent *SD* from three independent biological repeats. Unpaired two-tailed Student's *t* test between pCMV and pCMV-*PTEN* on Day five relative cell numbers: *t*(4) = 9.25, *p*=0.00076. Additional details for this experiment can be found at <https://osf.io/jgp6n/>.](elife-51019-fig5){#fig5}

Meta-analyses of original and replication effects {#s2-6}
-------------------------------------------------

We performed a meta-analysis using a random-effects model, where possible, to combine each of the effects described above as pre-specified in the confirmatory analysis plan ([@bib19]). To provide a standardized measure of the effect, a common effect size was calculated for each effect from the original and replication studies. Cohen's *d* is the standardized difference between two means using the pooled sample standard deviation, while the effect size Glass' delta is standardized difference between two means using the standard deviation of only the control group. Glass' delta was used when the variance between the two conditions were not equal, which occurred in the original study for some of the experiments. The estimate of the effect size of one study, as well as the associated uncertainty (i.e., confidence interval), compared to the effect size of the other study provides one approach to compare the original and replication results ([@bib8]; [@bib37]). Importantly, the width of the confidence interval (CI) for each study is a reflection of not only the confidence level (e.g., 95%), but also variability of the sample (e.g., *SD*) and sample size.

There were five comparisons of the Day five relative cell number data from DU145 cells that were transfected with siLUC, si-PTEN, si-PTENP1, or si-PTEN/PTENP1, which were reported in [Figure 1](#fig1){ref-type="fig"} of this study and Figure 2F of [@bib28]. In all comparisons the results were consistent when considering the direction of the effect; however the effect size point estimate of each study was not within the CI of the other study ([Figure 6A](#fig6){ref-type="fig"}). Further, the meta-analyses were not statistically significant for any of the comparisons (see [Figure 6A](#fig6){ref-type="fig"} figure legend). For three of the comparisons, the large CI of the meta-analyses along with statistically significant Cochran's *Q* tests (siLUC and si-PTEN, *p*=0.0253; siLUC and si-PTEN/PTENP1, *p*=0.0349; si-PTEN/PTENP1 and si-PTENP1, *p*=0.0235) suggest heterogeneity between the original and replication studies.

![Meta-analyses of each effect.\
Effect size and 95% confidence interval are presented for [@bib28], this replication study (RP:CB), and a random effects meta-analysis of those two effects. Cohen's *d* and Glass' delta are standardized differences between the two indicated measurements with the calculated effects for the original study effects reported as positive values. Sample sizes used in [@bib28] and RP:CB are reported under the study name. (**A**) These effects are related to the change in Day 5 relative cell numbers between the conditions reported in [Figure 1](#fig1){ref-type="fig"} of this study and Figure 2F of [@bib28]. Meta-analysis *p* values: siLUC and si-PTEN (*p*=0.394); siLUC and si-PTENP1 (*p*=0.129); siLUC and si-PTEN/PTENP1 (*p*=0.330); si-PTEN/PTENP1 and si-PTEN (*p*=0.202); si-PTEN/PTENP1 and si-PTENP1 (*p*=0.403). (**B**) These effects are related to the fold change differences in *PTEN* and *PTENP1* expression between the conditions reported in [Figure 2](#fig2){ref-type="fig"} of this study and Figure 2G of [@bib28]. Meta-analysis *p* values: *PTEN* expression between siLUC and si-PTEN (*p*=0.0013); *PTEN* expression between siLUC and si-PTENP1 (*p*=0.244); *PTEN* expression between siLUC and si-PTEN/PTENP1 (*p*=0.0019); *PTENP1* expression between siLUC and si-PTEN (*p*=0.225); *PTENP1* expression between siLUC and si-PTENP1 (*p*=0.060); *PTENP1* expression between siLUC and si-PTEN/PTENP1 (*p*=0.049). (**C**) These effects are related to the fold change differences in *PTENP1* expression between pCMV and pCMV-*PTEN*-3'UTR reported in [Figure 4](#fig4){ref-type="fig"} of this study and Figure 4A of [@bib28] (meta-analysis *p*=0.485). (**D**) These effects are related to the change in Day 5 relative cell numbers between pCMV and pCMV-*PTEN*-3'UTR reported in [Figure 5](#fig5){ref-type="fig"} of this study and Figure 4A of [@bib28] (meta-analysis *p*=0.0093). Additional details for these meta-analyses can be found at <https://osf.io/9yh6p/>.](elife-51019-fig6){#fig6}

*PTEN* and *PTENP1* mRNA expression were also examined in DU145 cells transfected with siLUC, si-PTEN, si-PTENP1, or si-PTEN/PTENP1, reported in [Figure 2](#fig2){ref-type="fig"} of this study and Figure 2G of [@bib28], in which a total of six comparisons were made. With the *PTEN* mRNA expression data, two comparisons (siLUC and si-PTEN; siLUC and si-PTEN/PTENP1) had effects in the same direction for both the original study and this replication attempt, with the CI of each study encompassing the effect size point estimate of the other study ([Figure 6B](#fig6){ref-type="fig"}). The third comparison (siLUC and si-PTENP1) had effects in the same direction for both studies, but the point estimate of the original study was not within the CI of the replication. Furthermore, the meta-analyses for the first two comparisons were statistically significant (siLUC and si-PTEN, *p*=0.0013; siLUC and si-PTEN/PTENP1, *p*=0.0019), while the meta-analysis of the third comparison was not statistically significant (siLUC and si-PTENP1, *p*=0.244). These meta-analyses suggest transfection with si-PTEN or si-PTEN/PTENP1 decreased *PTEN* expression, while with the si-PTENP1 transfection the null hypothesis that there is no difference in *PTEN* mRNA expression can not be rejected. With the *PTENP1* mRNA expression data, each of the three comparisons were consistent with respect to the direction of the effect; however, for each comparison the point estimate of the replication fell within the CI of the original study, but not vice versa. For the meta-analyses, two comparisons were not found to be statistically significant (siLUC and si-PTEN, *p*=0.225; siLUC and si-PTENP1, *p*=0.060), while one was (siLUC and si-PTEN/PTENP1, *p*=0.049). These meta-analyses suggest transfection with si-PTEN/PTENP1 decreases *PTENP1* expression, while with the two null hypotheses that there are no differences in *PTENP1* expression after transfection with si-PTEN or si-PTENP1 can not be rejected.

The original study results of the Western blot data examining PTEN protein levels after transfection with siRNAs targeting *PTEN* and/or *PTENP1* were reported for a single representative image ([Figure 2H](#fig2){ref-type="fig"}; [@bib28]). These values were compared to the values reported in this replication attempt and for each of the conditions tested the values reported in the original study were within the CI of this replication attempt ([Figure 3A](#fig3){ref-type="fig"}).

The effect sizes calculated from the *PTENP1* mRNA expression data between DU145 cells transfected with pCMV or pCMV-*PTEN*-3'UTR, which were reported in [Figure 4](#fig4){ref-type="fig"} of this study and Figure 4A of [@bib28], were in opposite directions between the two studies and the effect size point estimate of each study was not within the CI of the other study ([Figure 6C](#fig6){ref-type="fig"}). Furthermore, the meta-analysis was not statistically significant (*p*=0.485) with a large CI and a statistically significant Cochran's *Q* test (*p*=0.0425) that suggests heterogeneity between the original and replication studies.

For the Day five relative cell number data from DU145 cells transfected with pCMV or pCMV-*PTEN*-3'UTR, reported in [Figure 5](#fig5){ref-type="fig"} of this study and Figure 4A of [@bib28], the calculated effect sizes were consistent when considering direction ([Figure 6D](#fig6){ref-type="fig"}). The replication effect size point estimate fell within the CI of the original study, but not vice versa. A meta-analysis of these effects were found to be statistically significant (*p*=0.0093), suggesting transfection of DU145 cells with a plasmid designed to express the *PTEN* 3'UTR inhibited growth compared to a vector control plasmid.

This direct replication provides an opportunity to understand the present evidence of these effects. Any known differences, including reagents and protocol differences, were identified prior to conducting the experimental work and described in the Registered Report ([@bib19]). However, this is limited to what was obtainable from the original paper and through communication with the original authors, which means there might be particular features of the original experimental protocol that could be critical, but unidentified. So while some aspects, such as cell lines, number of cells plated, and the specific siRNA sequences were maintained, others were unknown or not easily controlled for. These include variables such as cell line genetic drift ([@bib15]; [@bib20]), and impacts of atmospheric oxygen on cell viability and growth ([@bib3]). Whether these or other factors influence the outcomes of this study is open to hypothesizing and further investigation, which is facilitated by direct replications and transparent reporting.

Materials and methods {#s3}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                    Designation                           Source or reference                                            Identifiers                                                                           Additional\
  (species) or resource                                                                                                                                                                                                       information
  -------------------------------- ------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  Cell line (*H. sapiens*, male)   DU145                                 ATCC                                                           cat\#:HTB-81; RRID:[CVCL_0105](https://scicrunch.org/resolver/CVCL_0105)              

  Sequence-based reagent           siGlo RISC-free siRNA                 Dharmacon                                                      cat\#:D-001600--01                                                                    

  Sequence-based reagent           siGENOME non-targeting siRNA \#2      Dharmacon                                                      cat\#:D-001210--02                                                                    

  Sequence-based reagent           *PTEN*-specific SMARTpool             Dharmacon                                                                                                                                            Reported in Supplementary Figure 6 (doi:[10.1038/nature09144](https://doi.org/10.1038/nature09144))

  Sequence-based reagent           *PTENP1*-specific SMARTpool           Dharmacon                                                                                                                                            Reported in Supplementary Figure 6 (doi:[10.1038/nature09144](https://doi.org/10.1038/nature09144))

  Sequence-based reagent           ON-TARGETplus siPTEN SMARTpool        Dharmacon                                                      cat\#:L-003023--00                                                                    

  Recombinant DNA reagent          pCMV                                  Agilent Technologies                                           cat\#:240071                                                                          

  Recombinant DNA reagent          pCMV-*PTEN*-3'UTR                     This paper                                                     RRID:[Addgene_97204](https://scicrunch.org/resolver/Addgene_97204)                    

  Antibody                         rabbit anti-PTEN                      Cell Signaling Technology                                      cat\#:9559; clone:138G5; RRID:[AB_390810](https://scicrunch.org/resolver/AB_390810)   1:1000 dilution

  Antibody                         mouse anti-HSP90                      BD Biosciences                                                 cat\#:610419; clone:68;\                                                              1:1000 dilution
                                                                                                                                        RRID:[AB_397798](https://scicrunch.org/resolver/AB_397798)                            

  Antibody                         HRP-conjugated goat anti-rabbit       Cell Signaling Technology                                      cat\#:7074; RRID:[AB_2099233](https://scicrunch.org/resolver/AB_2099233)              1:20,000 dilution

  Antibody                         HRP-conjugated horse anti-mouse       Cell Signaling\                                                cat\#:7076;\                                                                          1:20,000 dilution
                                                                         Technology                                                     RRID:[AB_330924](https://scicrunch.org/resolver/AB_330924)                            

  Software, algorithm              CFX Manager                           BioRad                                                         RRID:[SCR_017251](https://scicrunch.org/resolver/SCR_017251)                          version 3.1.1517.0823

  Software, algorithm              ImageJ                                doi:[10.1038/nmeth.2089](https://doi.org/10.1038/nmeth.2089)   RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)                          version 1.50a

  Software, algorithm              SoftMax Pro data\                     Molecular Devices                                              RRID:[SCR_014240](https://scicrunch.org/resolver/SCR_014240)                          version 4.6
                                   acquisition\                                                                                                                                                                               
                                   and analysis                                                                                                                                                                               

  Software, algorithm              R Project for statistical computing   <https://www.r-project.org>                                    RRID:[SCR_001905](https://scicrunch.org/resolver/SCR_001905)                          version 3.5.1
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

As described in the Registered Report ([@bib19]), we attempted a replication of the experiments reported in Figures 2F--H and 4A of [@bib28]. A detailed description of all protocols can be found in the Registered Report ([@bib19]) and are described below with additional information not listed in the Registered Report, but needed during experimentation.

Cell culture {#s3-1}
------------

DU145 cells (ATCC, cat\# HTB-81, RRID:[CVCL_0105](https://scicrunch.org/resolver/CVCL_0105)) were grown in RPMI 1640 supplemented with 10% Fetal Bovine Serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine. Cells were maintained at 37°C in a humidified atmosphere at 6% CO~2~. Quality control data for the experiments presented in [Figures 1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"} are available at <https://osf.io/zxuya/>, while data for the experiments presented in [Figures 4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"} are available at <https://osf.io/b4rt2/>. This includes results confirming the cell lines were free of mycoplasma contamination as well as STR DNA profiling of the cell lines, which were confirmed to be the indicated cell lines when queried against STR profile databases. Test for mycoplasma was performed by DDC Medical (Fairfield, Ohio) or using the MycoProbe Mycoplasma Detection Assay Kit (R and D Systems, cat\# CUL0001B, lot\# P104920). STR profile was performed by DDC Medical or Genetica Cell Line Testing (Burlington, North Carolina).

siRNA transfection and crystal violet proliferation assay {#s3-2}
---------------------------------------------------------

DU145 cells were seeded at 1.5 × 10^5^ cells per well in a 12 well plate and grown overnight. The next day cells were transfected using Dharmafect according to manufacturer's instructions with 25 nM siGlo RISC-free siRNA (Dharmacon, cat\# D-001600--01), 100 nM siGENOME non-targeting siRNA \#2 (siLuc; Dharmacon, cat\# D-001210--02), 100 nM *PTEN*-specific SMARTpool siPTEN; Dharmacon; sequences reported in Supplementary Figure 6 of [@bib28], 100 nM *PTENP1*-specific SMARTpool siPTENP1; Dharmacon; sequences reported in Supplementary Figure 6 of [@bib28], 100 nM ON-TARGETplus siPTEN SMARTpool (siPTEN/PTENP1; Dharmacon, cat\# L-003023--00), or left untransfected. After 24 hr, microscopy was performed on cells transfected with siGlo and untransfected cells to ascertain transfection efficiency, which was observed to be \>90%. Cells transfected with siLuc, siPTEN, siPTENP1, siPTEN/PTENP1, or untransfected were plated at 8,000 cells per well (in triplicate) in 12 well plates (enough for 6 days of measurements) with 2 ml of growth medium. Starting the day after plating (designated day 0), every 24 hr the crystal violet assay was performed as described in the Registered Report. Additionally, two additional cohorts (wells in triplicate) were included: unseeded (i.e., no cells) wells were treated with the Crystal Violet reagent (Blank treated) and unseeded wells left entirely untreated (Blank untreated). The average value from Blank treated was subtracted from each data point to correct for background staining of crystal violet to the plastic dish. For each independent biological repeat, average absorbance (OD~590~) for each condition was normalized by dividing the average absorbance of each day to the average absorbance for day 0 to calculate relative cell number. Area under the curve (AUC) was calculated for each condition of each biological repeat. Data files are available at <https://osf.io/xyefm/>.

siRNA transfection and quantitative PCR {#s3-3}
---------------------------------------

DU145 cells were seeded and transfected as described above in 'siRNA transfection and crystal violet proliferation assay'. 24 hr after transfection, total RNA was extracted with TRI Reagent (Sigma-Aldrich, cat\# T9424) added directly to each tissue culture dish with 1-bromo-3-chloropropane (Sigma-Aldrich, cat\# B9673) added to the homogenous lysate according to manufacturer's instructions. The RNA pellet was dried and stored at −80°C until shipped on dry-ice for quantitative PCR. RNA concentration and purity was determined (quality control data available at <https://osf.io/yh8z9/>). Total RNA was reverse transcribed into cDNA using a First-Strand cDNA Synthesis Kit (Sigma-Aldrich, cat\# GE27-9261-01) according to manufacturer's instructions. Reactions consisted of cDNA (2 µl of 10 ng/µl), qPCR Mastermix, ultrapure water, and primers (forward and reverse primers are listed in the Registered Report Protocol 3; [@bib19]). qRT-PCR reactions were performed in technical triplicate with QuantiTect Sybr Green PCR Kit (Qiagen, cat\# 204141) according to manufacturer's instructions. PCR cycling conditions were: one cycle: 95°C for 30 s -- 40 cycles: \[95°C for 10 s, 60°C for 30 s\] -- one cycle: 95°C for 30 s, 65--95°C (ramp 0.5°C every 5 s) using a BioRad CFX96 qPCR system (Hercules, California) and CFX Manager software (RRID:[SCR_017251](https://scicrunch.org/resolver/SCR_017251)), version 3.1.1517.0823. Negative controls containing no cDNA template were included. It was discovered the melting curves for *PTEN* and *PTENP1* were inconsistent and required repeating measuring. Relative expression levels were determined using the ∆∆Ct method. Data files are available at <https://osf.io/6zbdt/>.

siRNA transfection and western blot {#s3-4}
-----------------------------------

DU145 cells were seeded at 3.75 × 10^5^ cells per well in a six well plate and transfected with siRNAs as described above in 'siRNA transfection and crystal violet proliferation assay'. 48 hr after transfection, cells were prepared in lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 1 mM MgCl~2~, 1 mM ß-glycerophosphate, 1 mM NaF, and 1 mM Na~3~VO~4~), supplemented with protease inhibitors (Sigma-Aldrich, cat\# P8340) at manufacturer recommended concentrations. Lysed cells were incubated on ice for 30 min, gently sonicated for 3 to 4 bursts for 5 to 10 s, and centrifuged at 10,000x*g* for 10 min at 4°C before protein concentration of supernatant was quantified using a Bradford assay following manufacturer's instructions. Lysate samples (2.5 µg was used after optimization studies) were separated by 4--12% Tris Glycine SDS-PAGE gel electrophoresis with 5 µl of an ECL marker (Sigma-Aldrich, cat\# GERPN810) and then transferred to a nitrocellulose membrane as described in the Registered Report (Protocol 4; [@bib19]), except membranes were not washed with methanol prior to transfer. Transfer was confirmed by Ponceau S staining and membranes were blocked with 5% non-fat dry milk in 1X TBS with 0.1% Tween-20 (TBST) overnight at 4°C. Membranes were probed with the following primary antibodies diluted in 5% non-fat dry milk in TBST for 2 hr at room temperature: rabbit anti-PTEN \[clone 138G5\] (Cell Signaling Technology, cat\# 9559, RRID:[AB_390810](https://scicrunch.org/resolver/AB_390810)), 1:1000 dilution; mouse anti-HSP90 \[clone 68\] (BD Biosciences, cat\# 610419, RRID:[AB_397798](https://scicrunch.org/resolver/AB_397798)), 1:1000 dilution. Membranes were washed with TBST and incubated with secondary antibody diluted in 5% non-fat dry milk in TBST: HRP-conjugated goat anti-rabbit (Cell Signaling Technology, cat\# 7074, RRID:[AB_2099233](https://scicrunch.org/resolver/AB_2099233)), 1:20,000 dilution; HRP-conjugated horse anti-mouse (Cell Signaling Technology, cat\# 7076, RRID:[AB_330924](https://scicrunch.org/resolver/AB_330924)), 1:20,000 dilution. Membranes were washed with TBST and incubated with ECL reagent to visualize signals. Scanned Western blots were quantified using ImageJ software (RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)), version 1.50a ([@bib31]). Additional methods and data, including full Western blot images, are available at <https://osf.io/re87y/>.

PTEN 3'UTR plasmid generation {#s3-5}
-----------------------------

To generate pCMV-*PTEN*-3'UTR (deposited in Addgene, plasmid\# 97204; RRID:[Addgene_97204](https://scicrunch.org/resolver/Addgene_97204)), *PTEN* 3'UTR was amplified from HeLa genomic DNA (New England BioLabs, cat\# N4006) by PCR using KAPA Bio's HiFi Hotstart ReadyMix (Kapa Biosystems, cat\# KM2605) and the following primers (BamH1 forward primer: 5'-GGATCCTAGAGGAGCCGTCAAATCCA-3'; XhoI reverse primer: 5'-CTCGAGTGGACATCTGATTGGGATGA-3'). PCR cycling conditions were: one cycle: 98°C for 30 s -- 35 cycles: 98°C for 15 s, 64°C for 30 s, 72°C for 3 min 30 s -- one cycle: 72°C for 2 min. Following multiple unsuccessful attempts to clone the PCR product (\~3.3 kb) into the pCMV vector (Agilent Technologies, cat\# 240071) (direct, TOPO TA, Gibson assembly), we were successful by cloning partial fragments. The full-length *PTEN* 3'UTR PCR product was able to be broken into three fragments with the following primers and cycling conditions. PCR primers and parameters for CMV-*PTEN*-3'UTR minus middle SpeI-BstXI fragment: \[CMV-*PTEN*-3'UTR minus SpeI/BstXI forward primer: 5'-GAAATTTGGTGTCTTCAAATTATACCTTCAC-3'; CMV-*PTEN*-3'UTR minus SpeI/BstXI reverse primer: 5'-TTGAAAACTAGTAAAATAAGTGTAAGTTGTTGACTG-3'\]; one cycle: 98°C for 30 s -- 35 cycles: 98°C for 15 s, 58°C for 30 s, 72°C for 5 min -- 1 cycle: 72°C for 2 min. PCR primers and parameters for *PTEN*-3'UTR SpeI-BstXI fragment: \[*PTEN*-3'UTR SpeI-BstXI forward primer: 5'-CACTTATTTTACTAGTTTTCAATCATAATACCTG-3'; *PTEN*-3'UTR SpeI-BstXI reverse primer: 5'-TTGAAGACACCAAATTTCTGGAAAAAAAAACC-3'\]; 1 cycle: 98°C for 30 s -- 35 cycles: 98°C for 15 s, 58°C for 30 s, 72°C for 1 min -- 1 cycle: 72°C for 2 min. PCR products were gel purified and a 1:3 vector to insert ratio (0.02 pmoles: 0.06 pmoles) was used for the Gibson Assembly reactions (New England BioLabs, cat\# E5510S) according to manufacturer's instructions (50°C, 15 min). The assembly reaction was transformed into chemically competent *E. coli* (New England BioLabs, cat\# C3040I) according to manufacturer's instructions, except 1 hr phenotypic expression and plating temperatures were performed at 30°C. A positive clone was verified by sequencing. Additional methods are available at <https://osf.io/9stbg/>.

PTEN 3'UTR transfection and quantitative PCR {#s3-6}
--------------------------------------------

DU145 cells were seeded at 3.5 × 10^5^ cells per well in 60 mm plates and grown overnight. The next day cells were washed once with phosphate buffered saline (Sigma-Aldrich, cat\# D8537) before transfection using Effectene (Qiagen, cat\# 301425) according to manufacturer's instructions, or left untransfected. 1 µg plasmid (pCMV (empty vector) or pCMV-*PTEN*-3'UTR) was mixed with EC to a final volume of 150 µl followed by an addition of 8 µl of Enhancer, mixed for 1 s and then incubated at 25°C for 5 min. 25 µl of Effectene transfection reagent was added to the DNA-Enhancer sample and vortexed for 10 s before incubation at room temperature for 10 min. \~0.6 ml of growth medium was added to the transfection complex and mixed before added dropwise to dishes containing cells. 6 hr after transfection growth medium was replaced. 24 hr after transfection, total RNA was extracted and qPCR was performed as described above in 'siRNA transfection and quantitative PCR'. Data files are available at <https://osf.io/9etxj/>.

PTEN 3'UTR transfection and crystal violet proliferation assay {#s3-7}
--------------------------------------------------------------

DU145 cells were seeded and transfected as described above in '*PTEN* 3'UTR transfection and quantitative PCR' above. 6 hr after transfection cells were plated at 8,000 cell per well (in triplicate) in 12 well plates (enough for 6 days of measurements) with 2 ml of growth medium. Starting the day after plating (designated day 0), every 24 hr the crystal violet assay was performed as described in the Registered Report. Absorbance was recorded at 590 nm using SpectramaxPlus (Molecular Devices, Serial \# P02528) and SoftMax Pro data acquisition and analysis software (RRID:[SCR_014240](https://scicrunch.org/resolver/SCR_014240)), version 4.6. For each independent biological repeat, average absorbance (OD~590~) for each condition was normalized by dividing the average absorbance of each day to the average absorbance for day 0 to calculate relative cell number. Area under the curve (AUC) was calculated for each condition of each biological repeat. Raw data files are available at <https://osf.io/qf7xa/>.

Statistical analysis {#s3-8}
--------------------

Statistical analysis was performed with R software (RRID:[SCR_001905](https://scicrunch.org/resolver/SCR_001905)), version 3.5.1 ([@bib30]). All data, csv files, and analysis scripts are available on the OSF (<https://osf.io/yyqas/>). Confirmatory statistical analysis was pre-registered (<https://osf.io/2evzy>) before the experimental work began as outlined in the Registered Report ([@bib19]). Data were checked to ensure assumptions of statistical tests were met. When described in the results, the Bonferroni correction, to account for multiple tests, was applied to the alpha error or the *p*-value. The Bonferroni corrected value was determined by dividing the uncorrected value (0.05) by the number of tests performed. Although the Bonferroni method is conservative, it was accounted for in the power calculations to ensure sample size was sufficient. A meta-analysis of a common original and replication effect size was performed with a random effects model and the *metafor* R package ([@bib38]) (https://osf.io/9yh6p/). The original study data was extracted a priori from the published figures by estimating the value reported. The extracted data was published in the Registered Report ([@bib19]) and was used in the power calculations to determine the sample size for this study.

Data availability {#s3-9}
-----------------

Additional detailed experimental notes, data, and analysis are available on OSF (RRID:[SCR_003238](https://scicrunch.org/resolver/SCR_003238)) (<https://osf.io/yyqas/>; [@bib27]). This includes the R Markdown file (<https://osf.io/v3cag/>) that was used to compose this manuscript, which is a reproducible document linking the results in the article directly to the data and code that produced them ([@bib14]).

Deviations from registered report {#s3-10}
---------------------------------

The first protocol of the Registered Report was conducted, but it was identified after results were obtained that the si-miR-19b and si-miR-20a reagents listed in the Registered Report and used in the experiment were incorrect and thus are not included in this manuscript. The catalog numbers listed were for microRNA hairpin inhibitors not microRNA mimics. The original study does not list the catalog numbers and only lists the reagents as si-miR-19b or si-miR-20a. The expected result of reduced PTEN levels following overexpression of *miR-19b* or *miR-20a* that has been observed previously (e.g., [@bib25]; [@bib28]; [@bib36]) was not observed, which lead to the reevaluation of the reagent sources. Results obtained from using the inhibitors are available at <https://osf.io/fjdtn/>. The fifth and sixth protocol of the Registered Report (results presented in [Figures 4](#fig4){ref-type="fig"},[5](#fig5){ref-type="fig"}) used a plasmid that overexpressed *PTEN* 3'UTR that was generated as part of this replication attempt while the Registered Report indicated the plasmid would be shared by the original lab. The reason to remake the plasmid was because the original lab did not respond to our multiple follow up requests to share the plasmid with us following acceptance of the Registered Report. Details of how the plasmid was made are described in the '*PTEN 3'UTR plasmid generation*' section of the Materials and methods and the plasmid was deposited in Addgene (plasmid\# 97204; RRID:[Addgene_97204](https://scicrunch.org/resolver/Addgene_97204)) for the research community to access. Additional materials and instrumentation not listed in the Registered Report, but needed during experimentation are also listed above.
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Additional detailed experimental notes, data, and analysis are available on OSF (RRID:SCR_003238) (<https://osf.io/yyqas/>; Pandya et al., 2018). This includes the R Markdown file (<https://osf.io/v3cag/>) that was used to compose this manuscript, which is a reproducible document linking the results in the article directly to the data and code that produced them (Hartgerink, 2017).
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Decision letter after peer review:**

Thank you for submitting your article \"Replication Study: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Charles Sawyers as the Senior Editor. The reviewers have opted to remain anonymous.

The Reviewing Editor has drafted this decision to help you prepare a revised submission. We have appended the comments from the three reviewers to provide context for our seven points listed under \"Essential revisions.\"

Summary:

The manuscript by Kerwin and colleagues is reporting on data generated during the Reproducibility Project related to a paper published by Pandolfi\'s group (Poliseno et al., 2010) describing an RNA interaction function for the PTEN pseudogene. This paper was seen as a major advancement on the field of non-codingRNAs at the time of publication (see the comments in Nature 2010 and Nat Rev Cancer 2010). This publication inspired also a large effort by Chinnaiyan\'s group, which reported the translational landscape of expressed pseudogenes in human cancers. Therefore, the Poliseno et al. publication had a major impact on the field of non-codingRNAs independent of Dr. Pandolfi\'s own research.

There is also an error in the Registered Report (wrong reagent), but this is acknowledged in the subsection \"Deviations from Registered Report\" and these data should not be presented -- this section of the Replication Study is therefore missing. This is unfortunate, but there is no major problem since the data will not be presented.

The Replication Report indicates that several biological assays (e.g. proliferation) reported by Poliseno et al., 2010 were reproduced, but many of the molecular assays were not reproduced.

Essential revisions:

For clarity, the individual reviews are appended to this decision letter. It is recommended that these reviews are used to assist the preparation of a revised manuscript by addressing all the points that are raised. In particular, the following revisions should be fully addressed.

1\) The Abstract appears to have been prepared using a template and does not adequately convey the results and conclusion of the study.

2\) Proper citation of all the relevant literature that reports replication of the original study is required (see attached reviews).

3\) Figure 1. It appears that transfection alone has a phenotype -- is this a technical flaw in the performance of these experiments? The failure of si-PTEN to cause increased proliferation is surprising -- this also raises questions concerning a possible technical flaw in these studies.

4\) Figure 2. Please comment on the very large variability in the data obtained and the different normalization standards (36B4 vs Actin) used compared with Poliseno et al., 2010. Does this compromise the interpretation of these data -- if so, this should be stated.

5\) Figure 3. Please confirm the quantitation and statistical analysis (see attached reviews).

6\) Figure 4. Why was the PTEN3\'UTR plasmid employed different than the plasmid noted in the Registered Report (the one used by Poliseno et al., 2010)? What criteria were used to validate the plasmid that was used?

7\) A major conclusion of this study is that many of the molecular studies of Poliseno et al., 2010 were not reproduced in this specific analysis. This is a conclusion supported by the data presented. However, this conclusion should be reported in the context of noting that reproduction has been reported in the literature (including citations). The failure to replicate could be due to the particular experimental conditions (e.g. state of cell confluence, transfection-related toxicity, etc), perhaps the use of different normalization standards, the large variability of some of the data reported here that might prevent the detection of significant differences, and differences in technical ability between the personnel doing the studies. These (and other) issues should be noted as caveats to the overall study reported here.

Reviewer \#1:

This appears to be a properly executed Registered Report. The Introduction summarizes the target paper and states the history of the field with supporting evidence. The replication study itself indicates that the more molecular analyses (expression data) were poorly reproduced, but some of the more descriptive data (growth assays) were better reproduced. I did not see a major flaw in the reproduction study. Moreover, the last paragraph of the report notes a number of caveats that need to be applied to the interpretation of this study in comparison to the reference study. I have no recommendations for revision.

Reviewer \#2:

In this manuscript, Kerwin and colleagues have attempted to replicate Figure 2F-H and Figure 4A of the paper \"A coding-independent function of gene and pseudogene mRNAs regulates tumor biology\" (Poliseno et al., 2010). Overall, the results go in the same direction as the ones reported in the original paper (PTEN and PTENP1 are shown to be coregulated), but in some instances statistical significance is not reached and, in our opinion, this is at least in part due to the poor quality of the data.

The manuscript is less than convincing, for the reasons listed below:

\- The ONE western blot that is shown is quite poor in quality, which is disappointing given the excellent quality of PTEN antibodies. This should be repeated.

\- Standard deviations in qRT-PCR are quite large throughout paper.

\- Aim of each experiment is unclear, i.e. the main difference in expression levels/biological properties that each experiment wants to reproduce is never clearly stated. In the absence of any explanatory framework, the description of experimental results appears as a tedious list of statistical analyses.

\- Finally, the subsection \"Deviation from registered report\" is worrisome. The authors report that they could not reproduce Figure 1D of the original paper (miR-19b and miR-20a overexpression causes a decrease in both PTEN and PTENP1 RNA levels) because they realized they had used microRNA inhibitors instead of miRNA mimics, which means they had inhibited the microRNAs rather than overexpressing them! We recommend either removing this from manuscript or performing the replicating experiment as planned.

After reading this manuscript, we are even more convinced that the best validation of published data is the publication, by the original group as well as by independent groups, of more data that replicate the original findings. The sponging interaction between PTENP1 and PTEN, which was originally published by Poliseno et al., 2010, has been by now reproduced in 15 papers/studies, all by different groups. We have one in preparation ourselves, in which we confirm the original data obtained using RNA interference and we show that they hold true using cutting-edge CRISPR-based technologies.

As a final note, we find it puzzling that the authors themselves reference the literature (specifically, to the paper they intend to replicate as well as to others) to realize their mistake about the reproduction attempt of Figure 1D (subsection \"Deviation from registered report\": The expected result of reduced PTEN levels following overexpression of miR-19b or miR-20a\... has been observed previously (e.g. Luo et al., 2013; Poliseno et al., 2010; Tian et al., 2013; Wu et al., 2014)). Why in this instance did they choose to not replicate?

References included in the manuscript

\- The list of papers that confirm PTENP1 as sponging partner of PTEN needs to be extended and updated. The following references need to be added:

1\) Johnsson et al., 2013.

2\) Yu et al., 2014.

3\) Li et al., 2017.

4\) Qian et al., 2017.

5\) Shi, Tang and Su, 2017.

6\) Chen et al., 2018.

7\) Gao et al., 2019.

8\) Johnson et al., 2019.

9\) Wang et al., 2016.

10\) Lai et al., 2019.

\- Ynstead et al., 2018: the results described in this paper are not reported correctly.

\- The paper Wu et al., 2014 does not demonstrate directly that PTEN is targeted by miR-19b or 20a. So we are not sure why it is quoted in subsection \"Deviations from Registered Report\".

Figure 1 (replication of Figure 2F of the original paper)

\- There is a large difference btw untransfected and transfected cells. Did the authors check for transfection toxicity?

\- si-PTEN should speed up cell growth. Why is this not seen?

Figure 2 (replication of Figure 2G of the original paper)

\- The pattern of results is similar to the one reported in the Nature paper, however extremely large error bars, which prevent differences from reaching statistical significance, suggest that there was large variability in repeats. This in turn is suggestive of experimental consistency issues.

\- The use of 36B4 instead of Actin as internal control represents a difference compared to the experimental protocol followed in the original paper.

Figure 3 (replication of Figure 2H of the original paper)

\- The quality of western blot is very bad. This is surprising given the robustness and reliability of PTEN western antibodies in general. Should be repeated or better western displayed.

\- HSP90 is overexposed. Quantitation may be compromised.

\- It is not clear how quantitation was performed as results appear to be binned, whereas quantitation should be continuous ratios btw PTEN/HSP90.

\- The authors claim that the decrease in PTEN levels upon the transfection of si-PTEN and si-PTEN/PTENP1 is statistically significant, while that observed upon the transfection of si-PTENP1 is not. The latter is the main point that the experiment wants to make and clearly 1 replicate is skewing this data. Saying that there is no reproducibility just because 1 replicate is off compared to the other 4 is against common sense. Data interpretation is essential to the work of each scientist, as it is the one that allows to formulate the hypotheses that will guide the design of the experiments to come.

Figure 4 (replication of Figure 4A of the original paper)

\- Did the authors determine if their plasmid can successfully overexpress PTEN3\'UTR? This needs to be determined.

\- Why did the authors make this plasmid themselves, instead of using the one used in the original paper, as indicated in the Registered Report?

\- This result was replicated consistently in Tay et al., 2011 from same group (PMID: 22000013).

Reviewer \#3:

The manuscript by Kerwin and colleagues is reporting on data generated during the Reproducibility Project related to an important paper published by Pandolfi\'s group (Poliseno et al., 2010) describing an RNA interaction function for the PTEN pseudogene.

The same group of authors published in 2015 a registered report on how the confirmation workflow will be done that I reviewed and approved myself. This report was twice corrected on-line, once technically and once reporting the removal of the first two authors of the study with their inclusion in acknowledgements.

This Pandolfi group publication was seen as a major advancement on the field of non-codingRNAs at the time of publication (see the comments in Nature 2010 and Nat Rev Cancer 2010). This publication inspired also a large effort by Chinnaiyan\'s group who produced the translational landscape of expressed pseudogenes in human cancers. Therefore, the Poliseno et al., publication had, in fact, a major impact on the field of non-codingRNAs independent of Dr. Pandolfi\'s own research.

This is the basis of the selection of the paper to be reproduced, making consequently the report by Kerwin and colleagues more interesting regarding data reproducibility for a large spectrum of readers independently on the specific focus of their research. It has to be appreciated the effort and work and time commitment by Kerwin and colleagues on this.

1\) Regarding the Abstract, this report is from a series of reports on the same theme and has the wording pattern from other similar reports published from the same group. What is surprisingly missing from all these abstracts is the conclusion sentence that is a standard for scientific publications. Please add a conclusion: did this report generally confirmed or not the data from Poliseno et al., 2010? I would recommend also for future studies on other publications to have a conclusive statement in the Abstract.

2\) In Figure 1, I would add a second panel with the actual levels of downregulation of PTEN, PTENP1 and PTEN/PTENP1, and also compare these levels with the ones reported by Poliseno et al. If these are not reported in Nature paper from 2010, then this information has to be requested from Pandolfi\'s group. It is essential, as various levels of downregulation can give various phenotype effects.

3\) The lack of replication of reported data in subsection \"Quantitative PCR following transfected with siRNA against PTEN and/or PTENP1\", meaning the lack of significant variation of PTEN mRNA levels following PTENP1 knockdown and vice versa are problematic, as these are related to the core finding of Poliseno\'s et al. paper\... Starting from simple technical points, were the Î² actin levels by qRT-PCR in the replication study comparable with the ones from Poliseno\'s study? If not, then this can be an explanation. Second, was the confluence of cells in the experiment by Kerwin and colleagues\' for this particular experiment similar with the cell confluence levels used by Poliseno et al.? It is already reported that cell confluence significantly modifies the levels of expression of ncRNAs, see please a seminal paper by Mandel\'s group (Hwang et al., 2009). As this info is not reported in Nature paper and also is not used to be reported in publications, direct communication with the authors from Poliso et al., paper is important. Generally, as this is such an essential point for the ceRNA theory, the data have to be compared point by point between the two groups.

4\) For Figure 3B, please add the quantification results of PTEN protein levels. Same question as above: was the confluence of cells in the experiment by Kerwin and colleagues\' fir this particular experiment similar with the cell confluence levels for Poliseno et al.?

5\) The lack of replication of reported data in subsection \"Quantitative PCR following PTEN 3\` UTR transfection\", meaning the lack of effect of exogenous PTEN-3UTR on the expression of PTENP1 is also problematic regarding Poliseno\'s report\...Again, the levels of normalizers for the two sets of experiments, Kerwin and colleagues versus Poliseno et al., as well as cell confluence, the cell passage used for these studies, have to be compared side by side. If not possible, I suggest the inclusion of this points specifically in the discussion, as a knowledgeable reader can\'t draw conclusions without such information.

10.7554/eLife.51019.sa2

Author response

> Essential revisions:
>
> For clarity, the individual reviews are appended to this decision letter. It is recommended that these reviews are used to assist the preparation of a revised manuscript by addressing all the points that are raised. In particular, the following revisions should be fully addressed.
>
> 1\) The Abstract appears to have been prepared using a template and does not adequately convey the results and conclusion of the study.

We\'ve revised the abstract to include additional information, but we did not include a statement regarding whether this report generally confirmed (or not) the data from Poliseno et al., 2010, similar to our other reports. *eLife* has been publishing editors\' summaries from their perspective of whether the results were generally confirmed (or not) and since there is no agreement of what it means to confirm (or not) an original study we prefer to remain silent on making this claim in the individual replication reports. Finally, we will publish a final paper that summarizes the collective evidence of all the replications, which will provide a better platform for discussing this important and complex issue.

> 2\) Proper citation of all the relevant literature that reports replication of the original study is required (see attached reviews).

We have included additional literature as suggested by reviewer \#2.

> 3\) Figure 1. It appears that transfection alone has a phenotype -- is this a technical flaw in the performance of these experiments? The failure of si-PTEN to cause increased proliferation is surprising -- this also raises questions concerning a possible technical flaw in these studies.

We agree it is possible that transfection toxicity could be a variable at play in both the original and replication study, which the inclusion of the untransfected condition in the replication surfaces, a condition not reported in the original study. Visualization of the cells by microscopy revealed the transfected and untransfected cells were similar to each other. Another important difference is the replication showed a growth rate much higher in the control condition than in the original study, which reported little to no growth in control cells over the time course, but which is still lower than the untransfected condition. The impact of lipid-based transfection on cellular processes has been documented, so this is also not unexpected and illustrates the need for untransfected cells for proper interpretation. We have included these points and a further discussion on this point in the revised manuscript. We also agree the level of increased cell growth in the siPTEN condition compared to control was expected to be higher than observed in this replication attempt and have included this in the revised manuscript.

> 4\) Figure 2. Please comment on the very large variability in the data obtained and the different normalization standards (36B4 vs Actin) used compared with Poliseno et al., 2010. Does this compromise the interpretation of these data -- if so, this should be stated.

The variation between the biological repeats suggests variation in biology as well as any technical variation associated with the plating and transfection step of the experiment. We have included a discussion of the impact this has on interpretation of these data. The use of 36B4 as an additional internal control was asked of us during peer review of the Registered Report (<https://doi.org/10.7554/eLife.08245.002>). This point has been included in the revised manuscript.

> 5\) Figure 3. Please confirm the quantitation and statistical analysis (see attached reviews).

We have addressed the comments regarding quantitation and statistic in the attached reviews.

> 6\) Figure 4. Why was the PTEN3\'UTR plasmid employed different than the plasmid noted in the Registered Report (the one used by Poliseno et al., 2010)? What criteria were used to validate the plasmid that was used?

We have included the reason in the subsection \"Deviations from Registered Report\". In short, the original lab that offered to share the plasmid did not respond to our multiple follow up requests to share the plasmid with us following acceptance of the Registered Report. We also agree it is possible that although the plasmid was verified to be correct by sequencing that PTEN 3\'UTR was not expressed (or not expressed to the same level as the original study). We have raised this point in the revised manuscript as well as how differences in the level of expression could impact the results compared to the original study.

> 7\) A major conclusion of this study is that many of the molecular studies of Poliseno et al., 2010 were not reproduced in this specific analysis. This is a conclusion supported by the data presented. However, this conclusion should be reported in the context of noting that reproduction has been reported in the literature (including citations). The failure to replicate could be due to the particular experimental conditions (e.g. state of cell confluence, transfection-related toxicity, etc), perhaps the use of different normalization standards, the large variability of some of the data reported here that might prevent the detection of significant differences, and differences in technical ability between the personnel doing the studies. These (and other) issues should be noted as caveats to the overall study reported here.

We have revised the manuscript throughout to discuss these caveats and have addressed the specific reviewer comments related to these.

> Reviewer \#1:
>
> This appears to be a properly executed Registered Report. The Introduction summarizes the target paper and states the history of the field with supporting evidence. The replication study itself indicates that the more molecular analyses (expression data) were poorly reproduced, but some of the more descriptive data (growth assays) were better reproduced. I did not see a major flaw in the reproduction study. Moreover, the last paragraph of the report notes a number of caveats that need to be applied to the interpretation of this study in comparison to the reference study. I have no recommendations for revision.

Thank you.

> Reviewer \#2:
>
> In this manuscript, Kerwin and colleagues have attempted to replicate Figure 2F-H and Figure 4A of the paper \"A coding-independent function of gene and pseudogene mRNAs regulates tumor biology\" (Poliseno et al., 2010). Overall, the results go in the same direction as the ones reported in the original paper (PTEN and PTENP1 are shown to be coregulated), but in some instances statistical significance is not reached and, in our opinion, this is at least in part due to the poor quality of the data.
>
> The manuscript is less than convincing, for the reasons listed below:
>
> \- The ONE western blot that is shown is quite poor in quality, which is disappointing given the excellent quality of PTEN antibodies. This should be repeated.

We used the same PTEN antibody as the original study and optimized conditions based on the original protocol as stated in the Materials and methods section. We revised Figure 3 to include two exposures to help facilitate detection of PTEN. Further, all western blot images and exposures are available at <https://osf.io/n6vn3/>, which will be made public upon publication.

> \- Standard deviations in qRT-PCR are quite large throughout paper.

Further discussion on possible reasons for this are also included in the revised manuscript.

> \- Aim of each experiment is unclear, i.e. the main difference in expression levels/biological properties that each experiment wants to reproduce is never clearly stated. In the absence of any explanatory framework, the description of experimental results appears as a tedious list of statistical analyses.

The aim of each experiment is briefly stated at the beginning of each experiment section. However, we have revised the manuscript to better address the dependent and independent variables under investigation.

> \- Finally, the subsection \"Deviation from registered report\" is worrisome. The authors report that they could not reproduce Figure 1D of the original paper (miR-19b and miR-20a overexpression causes a decrease in both PTEN and PTENP1 RNA levels) because they realized they had used microRNA inhibitors instead of miRNA mimics, which means they had inhibited the microRNAs rather than overexpressing them! We recommend either removing this from manuscript or performing the replicating experiment as planned.

This experiment is not included in this manuscript as stated in the subsection \"Deviations from Registered Report\". The error occurred somewhere during the preparation of the Registered Report and was not caught during peer review, however because of the unexpected result we confirmed all details and identified this error and thus are not including the data/results in this manuscript.

> After reading this manuscript, we are even more convinced that the best validation of published data is the publication, by the original group as well as by independent groups, of more data that replicate the original findings. The sponging interaction between PTENP1 and PTEN, which was originally published by Poliseno et al., 2010, has been by now reproduced in 15 papers/studies, all by different groups. We have one in preparation ourselves, in which we confirm the original data obtained using RNA interference and we show that they hold true using cutting-edge CRISPR-based technologies.As a final note, we find it puzzling that the authors themselves reference the literature (specifically, to the paper they intend to replicate as well as to others) to realize their mistake about the reproduction attempt of Figure 1D (subsection \"Deviation from registered report\": The expected result of reduced PTEN levels following overexpression of miR-19b or miR-20a\... has been observed previously (e.g. Luo et al., 2013; Poliseno et al., 2010; Tian et al., 2013; Wu et al., 2014)). Why in this instance did they choose to not replicate?

We do not understand the final question \"Why in this instance did they choose to not replicate?\". Is the suggestion that because we cite the data from the original study, as well as other studies, we should not have chosen to replicate this specific experiment? The decisions over what papers and experiments to replicate were described in our overview paper of the project (<https://elifesciences.org/articles/04333>) and for this specific replication were discussed during peer review of the Registered Report (<https://elifesciences.org/articles/08245>).

> References included in the manuscript- The list of papers that confirm PTENP1 as sponging partner of PTEN needs to be extended and updated. The following references need to be added:
>
> 1\) Johnsson et al., 2013.
>
> 2\) Yu et al., 2014.
>
> 3\) Li et al., 2017.
>
> 4\) Qian et al., 2017.
>
> 5\) Shi, Tang and Su, 2017.
>
> 6\) Chen et al., 2018.
>
> 7\) Gao et al., 2019.
>
> 8\) Johnson et al., 2019.
>
> 9\) Wang et al., 2016.
>
> 10\) Lai et al., 2019.

We have included additional references in the revised manuscript in addition to the references that were already included on the role of PTEN/PTENP1 in cancer.

> \- Ynstead et al., 2018: The results described in this paper are not reported correctly.

Thank you for catching this error. We have revised the sentence referencing the results of Yndestad et al., 2018 to reflect that *PTEN* expression was decreased, not increased, in MCF7 cells when *PTENP1* was upregulated.

> \- The paper Wu et al., 2014 does not demonstrate directly that PTEN is targeted by miR-19b or 20a. So we are not sure why it is quoted in subsection \"Deviations from Registered Report\".

We have removed Wu et al., 2014 in the revised manuscript.

> Figure 1 (replication of Figure 2F of the original paper)- There is a large difference btw untransfected and transfected cells. Did the authors check for transfection toxicity?

We agree it is possible that transfection toxicity could be a variable at play in both the original and replication study, which the inclusion of the untransfected condition in the replication surfaces, a condition not reported in the original study. Visualization of the cells by microscopy revealed the transfected and untransfected cells were similar to each other. Another important difference is the replication showed a growth rate much higher in the control condition than in the original study, which reported little to no growth in control cells over the time course, but which is still lower than the untransfected condition. The impact of lipid-based transfection on cellular processes has been documented, so this is also not unexpected and illustrates the need for untransfected cells for proper interpretation. We have included these points and a further discussion on this point in the revised manuscript.

> \- si-PTEN should speed up cell growth. Why is this not seen?

We agree the level of increased cell growth in the siPTEN condition compared to control was expected to be higher than observed in this replication attempt and have included this in the revised manuscript.

> Figure 2 (replication of Figure 2G of the original paper)- The pattern of results is similar to the one reported in the Nature paper, however extremely large error bars, which prevent differences from reaching statistical significance, suggest that there was large variability in repeats. This in turn is suggestive of experimental consistency issues.

The variation between the biological repeats suggests variation in biology as well as any technical variation associated with the plating and transfection step of the experiment. We have included a discussion of the impact this has on detecting statistical significance.

> \- The use of 36B4 instead of Actin as internal control represents a difference compared to the experimental protocol followed in the original paper.

The use of 36B4 as an additional internal control was asked of us during peer review of the Registered Report (<https://doi.org/10.7554/eLife.08245.002>). This point has been included in the revised manuscript.

> Figure 3 (replication of Figure 2H of the original paper)- The quality of western blot is very bad. This is surprising given the robustness and reliability of PTEN western antibodies in general. Should be repeated or better western displayed.

We used the same PTEN antibody as the original study and optimized conditions based on the original protocol as stated in the Materials and methods. We revised Figure 3 to include two exposures to help facilitate detection of PTEN. Further, all western blot images and exposures are available at <https://osf.io/n6vn3/>, which will be made public upon publication.

> \- HSP90 is overexposed. Quantitation may be compromised.

Multiple exposures of PTEN and HSP90 were taken and used in quantitation.

> \- It is not clear how quantitation was performed as results appear to be binned, whereas quantitation should be continuous ratios btw PTEN/HSP90.

Additional details on quantitation has been added to the revised manuscript. Results are not binned, but are on a continuous scale, relative to siLuc (which is arbitrarily set to 1). We also revised the figure to create more separation in the individual data points where possible, but where values are similar they appear binned even though they are not.

> \- The authors claim that the decrease in PTEN levels upon the transfection of si-PTEN and si-PTEN/PTENP1 is statistically significant, while that observed upon the transfection of si-PTENP1 is not. The latter is the main point that the experiment wants to make and clearly 1 replicate is skewing this data. Saying that there is no reproducibility just because 1 replicate is off compared to the other 4 is against common sense. Data interpretation is essential to the work of each scientist, as it is the one that allows to formulate the hypotheses that will guide the design of the experiments to come.

There is no statement made in the manuscript about \'no reproducibility\'. The reviewer is correct the main test of the experiment was not statistically significant, but this comment appears to equate \'statistically significant\' with \'reproduced\' and vice versa. Failing to reject the null hypothesis does not mean we accept the null hypothesis, only that there is insufficient evidence at the predefined level of significance and power (sample size) to reject the null hypothesis. We also disagree with the comment that \'1 replicate is skewing the data\'. Unlike the original study that reported an N of 1, the variation of multiple biological repeats are shown in this replication study and necessary for appropriate interpretation.

> Figure 4 (replication of Figure 4A of the original paper)- Did the authors determine if their plasmid can successfully overexpress PTEN3\'UTR? This needs to be determined.

Thank you for raising this point. It is possible that although the plasmid was verified to be correct by sequencing that PTEN 3\'UTR was not expressed. We have raised this point in the revised manuscript as well as how differences in the level of expression could impact the results compared to the original study.

> \- Why did the authors make this plasmid themselves, instead of using the one used in the original paper, as indicated in the Registered Report?

We have included the reason in the subsection \"Deviations from Registered Report\". In short, the original lab that offered to share the plasmid did not respond to our multiple follow up requests to share the plasmid with us following acceptance of the Registered Report.

> \- This result was replicated consistently in Tay et al., 2011 from same group (PMID: 22000013).

This specific experiment (Figure 4A of the original paper and Figure 4 of this manuscript) that examined expression of *PTENP1* following overexpression of the *PTEN* 3\'UTR, does not seem to be reported in Tay et al., 2011. Although we do agree that Tay et al., 2011 extended the results of Poliseno et al., 2010 to identify additional ceRNAs that modulate PTEN through microRNA competition and have included this in the revised manuscript.

> Reviewer \#3:
>
> \[\...\] This Pandolfi group publication was seen as a major advancement on the field of non-codingRNAs at the time of publication (see the comments in Nature 2010 and Nat Rev Cancer 2010). This publication inspired also a large effort by Chinnaiyan\'s group who produced the translational landscape of expressed pseudogenes in human cancers. Therefore, the Poliseno et al., publication had, in fact, a major impact on the field of non-codingRNAs independent of Dr. Pandolfi\'s own research.
>
> This is the basis of the selection of the paper to be reproduced, making consequently the report by Kerwin and colleagues more interesting regarding data reproducibility for a large spectrum of readers independently on the specific focus of their research. It has to be appreciated the effort and work and time commitment by Kerwin and colleagues on this.
>
> 1\) Regarding the Abstract, this report is from a series of reports on the same theme and has the wording pattern from other similar reports published from the same group. What is surprisingly missing from all these abstracts is the conclusion sentence that is a standard for scientific publications. Please add a conclusion: did this report generally confirmed or not the data from Poliseno et al., 2010? I would recommend also for future studies on other publications to have a conclusive statement in the Abstract.

We\'ve revised the abstract to include additional information, but we did not include a statement regarding whether this report generally confirmed (or not) the data from Poliseno et al., 2010, similar to our other reports. *eLife* has been publishing editors\' summaries from their perspective of whether the results were generally confirmed (or not) and since there is no agreement of what it means to confirm (or not) an original study we prefer to remain silent on making this claim in the individual replication reports. Finally, we will publish a final paper that summarizes the collective evidence of all the replications, which will provide a better platform for discussing this important and complex issue.

> 2\) In Figure 1, I would add a second panel with the actual levels of downregulation of PTEN, PTENP1 and PTEN/PTENP1, and also compare these levels with the ones reported by Poliseno et al. If these are not reported in Nature paper from 2010, then this information has to be requested from Pandolfi\'s group. It is essential, as various levels of downregulation can give various phenotype effects.

We agree that various levels of downregulation can give various phenotype effects and have included this in the revised manuscript. Specific to this point, the downregulation of PTEN, PTENP1, and PTEN/PTENP1 are included in Figure 2 and directly compared to what was reported in Poliseno et al., 2010 in the discussion and in Figure 6. We have revised the transition between Figure 1 and Figure 2 to make this point clearer for readers.

> 3\) The lack of replication of reported data in subsection \"Quantitative PCR following transfected with siRNA against PTEN and/or PTENP1\", meaning the lack of significant variation of PTEN mRNA levels following PTENP1 knockdown and vice versa are problematic, as these are related to the core finding of Poliseno\'s et al. paper\... Starting from simple technical points, were the Î² actin levels by qRT-PCR in the replication study comparable with the ones from Poliseno\'s study? If not, then this can be an explanation. Second, was the confluence of cells in the experiment by Kerwin and colleagues\' for this particular experiment similar with the cell confluence levels used by Poliseno et al.? It is already reported that cell confluence significantly modifies the levels of expression of ncRNAs, see please a seminal paper by Mandel\'s group (Hwang et al., 2009). As this info is not reported in Nature paper and also is not used to be reported in publications, direct communication with the authors from Poliso et al., paper is important. Generally, as this is such an essential point for the ceRNA theory, the data have to be compared point by point between the two groups.

We did have direct contact with the original authors during the design phase of the project, which resulted in the Registered Report, but did not receive the data or information raised in this comment. We agree that these are important points to consider and have included these in the revised manuscript despite the inability to provide a point by point comparison of the levels.

> 4\) For Figure 3B, please add the quantification results of PTEN protein levels. Same question as above: was the confluence of cells in the experiment by Kerwin and colleagues\' fir this particular experiment similar with the cell confluence levels for Poliseno et al.?

The quantification of the PTEN protein levels, normalized to HSP90 are included in Figure 3A. We have revised the 3B to include the quantified values for this biological repeat for added clarity.

> 5\) The lack of replication of reported data in subsection \"Quantitative PCR following PTEN 3\` UTR transfection\", meaning the lack of effect of exogenous PTEN-3UTR on the expression of PTENP1 is also problematic regarding Poliseno\'s report\...Again, the levels of normalizers for the two sets of experiments, Kerwin and colleagues versus Poliseno et al., as well as cell confluence, the cell passage used for these studies, have to be compared side by side. If not possible, I suggest the inclusion of this points specifically in the discussion, as a knowledgeable reader can\'t draw conclusions without such information.

We agree that these are important points to consider and have included these in the revised manuscript despite the inability to provide a point by point comparison of the levels.

[^1]: Biogen, Cambridge, United States.
